{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:49:02Z","timestamp":1794890942506,"version":"4.9.1"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.biopha.2025.118117","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T14:40:52Z","timestamp":1746283252000},"page":"118117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Neuropeptide Y receptors 1 and 2 as molecular targets in prostate and breast cancer therapy"],"prefix":"10.1016","volume":"187","author":[{"given":"Katarina","family":"Tomi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kostev\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bassanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41598-020-57920-z","article-title":"Neuropeptide receptor genes GHSR and NMUR1 are candidate epigenetic biomarkers and predictors for surgically treated patients with oropharyngeal cancer","volume":"10","author":"Misawa","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118117_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrc3690","article-title":"Oncogenic protein interfaces: small molecules, big challenges","volume":"14","author":"Nero","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2025.118117_bib3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Mol. Pharm."},{"issue":"18","key":"10.1016\/j.biopha.2025.118117_bib4","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1073\/pnas.79.18.5485","article-title":"Neuropeptide Y: complete amino acid sequence of the brain peptide","volume":"79","author":"Tatemoto","year":"1982","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib5","doi-asserted-by":"crossref","first-page":"9962","DOI":"10.3390\/ijms24129962","article-title":"Neuropeptide Y peptide family and cancer: antitumor therapeutic strategies","volume":"24","author":"S\u00e1nchez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118117_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3389\/fchem.2020.00571","article-title":"Peptide-drug conjugates and their targets in advanced cancer therapies","volume":"8","author":"Hoppenz","year":"2020","journal-title":"Front. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib7","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/molecules27123726","article-title":"PET imaging of the neuropeptide Y system: a systematic review","volume":"27","author":"Fonseca","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41467-022-28510-6","article-title":"Structural basis of neuropeptide Y signaling through Y1 receptor","volume":"13","author":"Park","year":"2022","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib9","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1021\/acs.bioconjchem.6b00568","article-title":"Theranostic nanocages for imaging and photothermal therapy of prostate cancer cells by active targeting of neuropeptide-Y receptor","volume":"27","author":"Avvakumova","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib10","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1210\/en.2005-0925","article-title":"Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells","volume":"147","author":"Ruscica","year":"2006","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ijc.26350","article-title":"Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line","volume":"131","author":"Medeiros","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118117_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2013.00005","article-title":"Neuropeptide Y receptors: how to get subtype selectivity","volume":"4","author":"Pedragosa-Badia","year":"2013","journal-title":"Front. Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib13","doi-asserted-by":"crossref","first-page":"9962","DOI":"10.3390\/ijms24129962","article-title":"Neuropeptide Y peptide family and cancer: antitumor therapeutic strategies","volume":"24","author":"S\u00e1nchez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118117_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.npep.2012.08.005","article-title":"Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis","volume":"46","author":"Holzer","year":"2012","journal-title":"Neuropeptides"},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0196-9781(01)00601-5","article-title":"Distribution of pancreatic polypeptide and peptide YY","volume":"23","author":"Ekblad","year":"2002","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0196-9781(01)00331-X","article-title":"Origins of the many NPY-family receptors in mammals","volume":"22","author":"Larhammar","year":"2001","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib17","article-title":"NPY1R (neuropeptide Y receptor Y1)","author":"Ruscica","year":"2011","journal-title":"Atlas Genet. Cytogenet. Oncol. Haematol."},{"key":"10.1016\/j.biopha.2025.118117_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0167-0115(98)00054-8","article-title":"Is there really an NPY Y3 receptor?","volume":"75\u201376","author":"Lee","year":"1998","journal-title":"Regul. Pept."},{"issue":"11","key":"10.1016\/j.biopha.2025.118117_bib19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/emmm.201000100","article-title":"Therapeutic potential of neuropeptide Y (NPY) receptor ligands","volume":"2","author":"Brothers","year":"2010","journal-title":"EMBO Mol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib20","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/molecules27123726","article-title":"PET imaging of the neuropeptide Y system: a systematic review","volume":"27","author":"Fonseca","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biopha.2025.118117_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.npep.2004.05.007","article-title":"Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts","volume":"38","author":"Pedrazzini","year":"2004","journal-title":"Neuropeptides"},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011148","article-title":"The cyclic AMP pathway","volume":"4","author":"Sassone-Corsi","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(24)01352-8","article-title":"XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors","volume":"50","author":"Michel","year":"1998","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/nyas.14100","article-title":"Peptide receptors as cancer drug targets","volume":"1455","author":"Moody","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118117_bib25","doi-asserted-by":"crossref","first-page":"2200111","DOI":"10.1002\/adbi.202200111","article-title":"Neuropeptides in Cancer: friend and foe?","volume":"6","author":"Wu","year":"2022","journal-title":"Adv. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118117_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1139\/Y08-054","article-title":"Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth","volume":"86","author":"Pons","year":"2008","journal-title":"Can. J. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2025.118117_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.705499","article-title":"Update on the role of neuropeptide Y and other related factors in breast cancer and osteoporosis","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118117_bib28","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2967\/jnumed.114.142000","article-title":"Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors","volume":"55","author":"Morgat","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10555-024-10237-z","article-title":"Neuropeptide Y in cancer\u2014biological functions and potential clinical implications","volume":"44","author":"Sigorski","year":"2025","journal-title":"Cancer Metastas. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/rb\/rbv013","article-title":"Neuropeptide Y receptors: a promising target for cancer imaging and therapy","volume":"2","author":"Li","year":"2015","journal-title":"Regen. Biomater."},{"issue":"9","key":"10.1016\/j.biopha.2025.118117_bib31","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.3390\/molecules27092734","article-title":"Development of neuropeptide Y and cell-penetrating peptide MAP adsorbed onto lipid nanoparticle surface","volume":"27","author":"Silva","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12885-023-10993-1","article-title":"Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling","volume":"23","author":"Pascetta","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/jsre.1998.5528","article-title":"Peptide YY inhibits growth of human breast cancerin vitroandin vivo","volume":"82","author":"Gris\u00e9","year":"1999","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.biopha.2025.118117_bib34","article-title":"International agency for research on cancer","author":"Observatory","year":"2024","journal-title":"Glob. Cancer Obs."},{"issue":"7","key":"10.1016\/j.biopha.2025.118117_bib35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00259-002-0794-5","article-title":"Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting","volume":"29","author":"Reubi","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib36","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1038\/s41598-022-05949-7","article-title":"NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer","volume":"12","author":"Bhat","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3892\/ol.2014.2721","article-title":"NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients","volume":"9","author":"Liu","year":"2015","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.biopha.2025.118117_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1158\/1541-7786.MCR-09-0301","article-title":"Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line","volume":"8","author":"Sheriff","year":"2010","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2025.118117_bib39","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1158\/0008-5472.CAN-05-2744","article-title":"Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line","volume":"66","author":"Amlal","year":"2006","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.118117_bib40","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1039\/C9BM00337A","article-title":"A Y 1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer","volume":"7","author":"Wang","year":"2019","journal-title":"Biomater. Sci."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2025.118117_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0163-7258(02)00174-2","article-title":"Cholinergic innervation and function in the prostate gland","volume":"94","author":"Ventura","year":"2002","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118117_bib42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1055-9965.EPI-05-0752","article-title":"Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis","volume":"15","author":"Rasiah","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"10","key":"10.1016\/j.biopha.2025.118117_bib43","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1021\/pr400547s","article-title":"Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a Prostate Cancer Biomarker Polypeptide","volume":"12","author":"Ueda","year":"2013","journal-title":"J. Proteome Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0959-8049(96)00402-9","article-title":"Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma","volume":"33","author":"Mack","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118117_bib45","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1093\/annonc\/12.suppl_2.S27","article-title":"Expression of neuropeptide Y receptors in human prostate cancer cells","volume":"12","author":"Magni","year":"2001","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.peptides.2006.08.045","article-title":"Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer","volume":"28","author":"Ruscica","year":"2007","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.biopha.2025.118117_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1442-2042.2001.00250.x","article-title":"Effect of prostatic neuropeptides on migration of prostate cancer cell lines","volume":"8","author":"Nagakawa","year":"2001","journal-title":"Int. J. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/pros.24081","article-title":"Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance","volume":"81","author":"Ding","year":"2021","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/labinvest.3700009","article-title":"Neuropeptide Y receptor expression in human primary ovarian neoplasms","volume":"84","author":"K\u00f6rner","year":"2004","journal-title":"Lab. Invest"},{"issue":"24","key":"10.1016\/j.biopha.2025.118117_bib50","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1158\/1078-0432.CCR-04-0821","article-title":"High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia","volume":"10","author":"K\u00f6rner","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118117_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/NEN.0b013e318180e618","article-title":"Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors","volume":"67","author":"K\u00f6rner","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118117_bib52","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ijc.20948","article-title":"Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas","volume":"115","author":"K\u00f6rner","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"41","key":"10.1016\/j.biopha.2025.118117_bib53","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1038\/onc.2010.301","article-title":"Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy","volume":"29","author":"Lu","year":"2010","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.biopha.2025.118117_bib54","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1038\/onc.2014.253","article-title":"Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance","volume":"34","author":"Czarnecka","year":"2015","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2025.118117_bib55","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/0008-5472.CAN-04-2192","article-title":"Differential effects of neuropeptide Y on the growth and vascularization of neural crest\u2013derived tumors","volume":"65","author":"Kitlinska","year":"2005","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2025.118117_bib56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mce.2011.01.021","article-title":"High expression of NPY receptors in the human testis","volume":"337","author":"K\u00f6rner","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118117_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.118117_bib58","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2025.118117_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med."},{"issue":"10","key":"10.1016\/j.biopha.2025.118117_bib60","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1074\/jbc.M608902200","article-title":"Receptor subtype-specific docking of Asp6.59 with C-terminal Arginine residues in Y receptor ligands","volume":"282","author":"Merten","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41467-021-21030-9","article-title":"Structural basis for ligand recognition of the neuropeptide Y Y2 receptor","volume":"12","author":"Tang","year":"2021","journal-title":"Nat. Commun."},{"issue":"7702","key":"10.1016\/j.biopha.2025.118117_bib62","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41586-018-0046-x","article-title":"Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor","volume":"556","author":"Yang","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cellsig.2008.09.007","article-title":"Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization","volume":"21","author":"Lindner","year":"2009","journal-title":"Cell. Signal"},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1432-1033.1994.0947b.x","article-title":"Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y 1 and Y 2 receptors with distinguished conformations","volume":"225","author":"Beck-Sickinger","year":"1994","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E","article-title":"Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family","volume":"6","author":"Cabrele","year":"2000","journal-title":"J. Pept. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1021\/jm00055a010","article-title":"Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogs","volume":"36","author":"Kirby","year":"1993","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.biopha.2025.118117_bib67","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1016\/j.bmcl.2011.06.136","article-title":"The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the neuropeptide Y Y2 receptor","volume":"21","author":"Swanson","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10555-024-10237-z","article-title":"Neuropeptide Y in cancer\u2014biological functions and potential clinical implications","volume":"44","author":"Sigorski","year":"2025","journal-title":"Cancer Metastas. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib69","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0026-895X(24)12616-8","article-title":"Identification of potent and selective neuropeptide Y Y1 receptor agonists with orexigenic activity in vivo","volume":"60","author":"Mullins","year":"2001","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1073\/pnas.87.1.182","article-title":"[Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist","volume":"87","author":"Fuhlendorff","year":"1990","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118117_bib71","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1021\/jm101514m","article-title":"Incorporation of ortho -Carbaboranyl- N \u03b5 -Modified -Lysine into Neuropeptide Y Receptor Y 1 - and Y 2 -Selective Analogues","volume":"54","author":"Ahrens","year":"2011","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118117_bib72","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/anie.200905008","article-title":"Breast-cancer diagnosis by neuropeptide\u2005Y analogues: from synthesis to clinical application","volume":"49","author":"Khan","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"issue":"10","key":"10.1016\/j.biopha.2025.118117_bib73","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1046\/j.1432-1327.2001.02161.x","article-title":"Novel analogues of neuropeptide Y with a preference for the Y 1 -receptor","volume":"268","author":"S\u00f6ll","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118117_bib74","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00007a012","article-title":"Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at the Y1-type receptor","volume":"38","author":"Leban","year":"1995","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib75","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.bmcl.2009.12.068","article-title":"Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging","volume":"20","author":"Gu\u00e9rin","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib76","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/psc.1188","article-title":"First selective agonist of the neuropeptide Y1 -receptor with reduced size","volume":"15","author":"Zwanziger","year":"2009","journal-title":"J. Pept. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2025.118117_bib77","doi-asserted-by":"crossref","first-page":"10667","DOI":"10.1073\/pnas.0912782107","article-title":"G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake","volume":"107","author":"Hild","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2025.118117_bib78","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.3390\/ijms23158322","article-title":"A second life for MAP, a model amphipathic peptide","volume":"23","author":"Silva","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118117_bib79","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bmcl.2012.11.110","article-title":"Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells","volume":"23","author":"Shrivastava","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6587","key":"10.1016\/j.biopha.2025.118117_bib80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/382168a0","article-title":"A receptor subtype involved in neuropeptide-Y-induced food intake","volume":"382","author":"Gerald","year":"1996","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.biopha.2025.118117_bib81","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1074\/jbc.RA119.009160","article-title":"Design and development of stapled transmembrane peptides that disrupt the activity of G-protein\u2013coupled receptor oligomers","volume":"294","author":"Botta","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/molecules26010013","article-title":"Pharmacological characterization of \u00b5-opioid receptor agonists with biased G protein or \u03b2-arrestin signaling, and computational study of conformational changes during receptor activation","volume":"26","author":"Piekielna-Ciesielska","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.biopha.2025.118117_bib83","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cbpa.2008.10.015","article-title":"Peptides and peptidomimetics as prototypes","volume":"12","author":"Wennemers","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118117_bib84","article-title":"Peptide and peptidomimetic assemblies in dynamic combinatorial chemistry","volume":"5","author":"Rodrigues","year":"2023","journal-title":"ChemSystemsChem"},{"issue":"17","key":"10.1016\/j.biopha.2025.118117_bib85","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/cmdc.202000430","article-title":"Identification of a suitable peptidic molecular platform for the development of NPY(Y 1)R-specific imaging agents","volume":"15","author":"Krieger","year":"2020","journal-title":"ChemMedChem"},{"issue":"7","key":"10.1016\/j.biopha.2025.118117_bib86","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2174\/1568026618666180518095255","article-title":"The hydrocarbon staple beyond: recent advances towards stapled peptide therapeutics that target protein-protein interactions","volume":"18","author":"Hillman","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bmc.2012.10.026","article-title":"Cyclic analogs of galanin and neuropeptide Y by hydrocarbon stapling","volume":"21","author":"Green","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118117_bib88","doi-asserted-by":"crossref","first-page":"17640","DOI":"10.1021\/acsanm.2c03409","article-title":"Bonding of neuropeptide Y on graphene oxide for drug delivery applications to the central nervous system","volume":"5","author":"Cellot","year":"2022","journal-title":"ACS Appl. Nano Mater."},{"issue":"9","key":"10.1016\/j.biopha.2025.118117_bib89","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1021\/acsami.5b00270","article-title":"Neuropeptide Y Y 1 Receptors meditate targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy","volume":"7","author":"Li","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2011.03.011","article-title":"The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer","volume":"131","author":"Zhang","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13550-020-0612-8","article-title":"Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides","volume":"10","author":"Chastel","year":"2020","journal-title":"EJNMMI Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118117_bib92","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1038\/s41598-022-13227-9","article-title":"Assessing sequence-based protein\u2013protein interaction predictors for use in therapeutic peptide engineering","volume":"12","author":"Charih","year":"2022","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2025.118117_bib93","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cels.2021.08.010","article-title":"D-SCRIPT translates genome to phenome with sequence-based, structure-aware, genome-scale predictions of protein-protein interactions","volume":"12","author":"Sledzieski","year":"2021","journal-title":"Cell Syst."},{"key":"10.1016\/j.biopha.2025.118117_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.669431","article-title":"In silico approaches for the design and optimization of interfering peptides against protein\u2013protein interactions","volume":"8","author":"Hashemi","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"8","key":"10.1016\/j.biopha.2025.118117_bib95","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1078-0432.CCR-18-2912","article-title":"Depression-induced neuropeptide Y secretion promotes prostate cancer growth by recruiting myeloid cells","volume":"25","author":"Cheng","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:59:56Z","timestamp":1759003196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":95,"alternative-id":["S0753332225003117"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118117","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropeptide Y receptors 1 and 2 as molecular targets in prostate and breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118117"}}